VetDC (Fort Collins) won the 2012 Venture Showcase competition at the 2012 BioWest Conference and Expo yesterday at the Marriott City Center Denver, receiving the $7,500 cash prize. The announcement is made by April Giles, Colorado BioScience Association (CBSA) Executive Vice President who says this year's Venture Showcase was made possible by sponsors Dorsey and Whitney LLP, EKS and H and The Metro Denver Economic Development Corporation. BioWest, the Rocky Mountain Region's premier medical device and biotechnology conference, is organized by the CBSA and held every other year.
VetDC is an emergent veterinary biotechnology company that licenses innovative human biomedical technologies to address serious medical needs in companion animals. By aligning with CSU's top-ranked veterinary school, VetDC has unique capabilities to develop animal therapies, resulting in speed to market, risk reduction, and capital preservation. VetDC has assembled a proven team with regulatory, CMC, and clinical expertise. VetDC's lead candidate, VDC-1101, is an anti-cancer drug with extensive animal data. VDC-1101 is expected to launch in 2014 with $50M peak revenue potential. In 2011, VetDC secured funding from the Colorado Institute for Drug, Device and Diagnostic Development (CID4). VetDC President/CEO Steven Roy made the presentation at the Venture Showcase. For more information, visit: http://www.vet-dc.com.
“The Venture showcase announcement is the capstone to the BioWest Conference," Giles explains."It creates a huge buzz in the industry for the up-and-coming companies chosen to compete. We are very proud to announce VetDC as this year's winner.”
The Venture Showcase format allowed each company’s lead executive to make a 15-minute presentation with slides explaining their technology and business plan to a panel of judges in front of a live audience. This year's judging panel included the following bioscience experts and venture capitalists:
• Joe Adams, Partner, EKS&H
• Robert Chicoski, Partner, Saturn Partners
• Mike Handley, Senior Managing Partner and Executive Director, Level 5 Partners
• Ned Scheetz, Managing Director, Aphelion Capital
• Michael Weiner, Partner, Dorsey
No comments:
Post a Comment